{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:10:48Z","timestamp":1787238648901,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.rdc.2004.01.004","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:30Z","timestamp":1113821610000},"page":"311-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of rheumatoid arthritis with etanercept"],"prefix":"10.1016","volume":"30","author":[{"given":"Mark C","family":"Genovese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2004.01.004_BIB1","unstructured":"Amgen Corporation. Enbrel (etanercept) prescribing information. Thousand Oaks (CA). October 2002"},{"key":"10.1016\/j.rdc.2004.01.004_BIB2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1177\/106002809703101111","article-title":"Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis","volume":"31","author":"Murray","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rdc.2004.01.004_BIB3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2165\/00003495-199957060-00014","article-title":"Etanercept: a review of its use in rheumatoid arthritis","volume":"57","author":"Jarvis","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.rdc.2004.01.004_BIB4","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","article-title":"Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists","volume":"151","author":"Mohler","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.rdc.2004.01.004_BIB5","first-page":"233","article-title":"New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis","volume":"9","author":"Breedveld","year":"1998","journal-title":"Eur Cytokine Netw"},{"issue":"Suppl I","key":"10.1016\/j.rdc.2004.01.004_BIB6","first-page":"165","article-title":"Etanercept: therapeutic use in patients with rheumatoid arthritis","volume":"58","author":"Garrison","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2004.01.004_BIB7","first-page":"1849","article-title":"Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis","volume":"23","author":"Moreland","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2004.01.004_BIB8","first-page":"S229","article-title":"Enbrel (etanercept) pharmacokinetics in patients with rheumatoid arthritis","volume":"43","author":"Kremer","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2004.01.004_BIB9","article-title":"Once-weekly administration of 50 mg etanercept (Enbrel): results of a phase 3 multicenter clinical trial [abstract]","volume":"62","author":"Keystone","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2004.01.004_BIB10","first-page":"1118","article-title":"Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers","volume":"17","author":"Lebsack","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rdc.2004.01.004_BIB11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1345\/aph.19126","article-title":"The pharmacokinetics of etanercept in healthy volunteers","volume":"34","author":"Korth-Bradley","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rdc.2004.01.004_BIB12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2004.01.004_BIB13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2004.01.004_BIB14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2004.01.004_BIB15","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/art.11142","article-title":"Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations","volume":"48","author":"Kremer","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB16","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2004.01.004_BIB17","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB18","unstructured":"Amgen. Enbrel combination therapy inhibited progression of joint damage and offered significant rheumatoid arthritis symptom relief in new clinical study [press release]. Thousand Oaks (CA): June 20, 2003"},{"issue":"12","key":"10.1016\/j.rdc.2004.01.004_BIB19","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M","article-title":"Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis","volume":"43","author":"Bendele","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2004.01.004_BIB20","article-title":"A randomized double-blind controlled study evaluating the safety and efficacy of etanercept vs etanercept plus anakinra in patients with rheumatoid arthritis [abstract]","volume":"62","author":"Genovese","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2004.01.004_BIB21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2004.01.004_BIB22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.rdc.2004.01.004_BIB23","first-page":"S90","article-title":"Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial [abstract]","volume":"44","author":"Mease","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2004.01.004_BIB24","first-page":"S196","article-title":"Etanercept (ENBREL) inhibits radiographic progression in patients with psoriatic arthritis [abstract]","volume":"46","author":"Ory","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB25","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2004.01.004_BIB26","article-title":"Etanercept (Enbrel) improves signs and symptoms of ankylosing spondylitis: results of a phase 3 multicenter clinical trial [abstract]","volume":"62","author":"Davis","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2004.01.004_BIB27","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener's granulomatosus. A six-month open-label trial to evaluate safety","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/sarh.2003.50022","article-title":"Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis","volume":"33","author":"Stokes","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.46.3.197","article-title":"Studies with an enthesitis index as a method of clinical assessment in ankylosing spondylitis","volume":"46","author":"Mander","year":"1987","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2004.01.004_BIB30","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB31","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB32","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2004.01.004_BIB33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing gents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB34","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2004.01.004_BIB36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.410300510","article-title":"Anti-tumor necrosis factor therapy abrogates autoimmune demyelination","volume":"30","author":"Selmaj","year":"1991","journal-title":"Ann Neurol"},{"key":"10.1016\/j.rdc.2004.01.004_BIB37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.rdc.2004.01.004_BIB38","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2004.01.004_BIB39","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.10939","article-title":"Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives","volume":"48","author":"Ekstrom","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isom\u00e4ki","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.rdc.2004.01.004_BIB42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.rdc.2004.01.004_BIB43","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkj\u00e6r","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rdc.2004.01.004_BIB44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.43.2.128","article-title":"Cancer morbidity in rheumatoid arthritis","volume":"43","author":"Prior","year":"1984","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1A","key":"10.1016\/j.rdc.2004.01.004_BIB45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0002-9343(85)90246-3","article-title":"Occurrence of malignant neoplasms in the Rochester, Minnestoa, rheumatoid arthritis cohort","volume":"78","author":"Katusic","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2004.01.004_BIB46","first-page":"809","article-title":"Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry","volume":"18","author":"Matteson","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2004.01.004_BIB47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/03009749509099305","article-title":"The risk of cancer in rheumatoid patients in Japan","volume":"24","author":"Moritomo","year":"1995","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2004.01.004_BIB48","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.1780400906","article-title":"Rheumatoid arthritis and the risk of malignancy","volume":"40","author":"Cibere","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB49","first-page":"S188","article-title":"Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients","volume":"41","author":"Wolfe","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.004_BIB50","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/cncr.2820690510","article-title":"Lymphoma in inflammatory bowel disease","volume":"69","author":"Greenstein","year":"1992","journal-title":"Cancer"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X04000183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X04000183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:56:23Z","timestamp":1760180183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X04000183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0889857X04000183"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2004.01.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of rheumatoid arthritis with etanercept","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2004.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}